Rapid Micro Biosystems Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rapid Micro Biosystems (RPID).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$5Upside to Avg. PT+604.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 29, 2026	Roth Capital	Max Masucci	Initiate	Buy	$3
May 29, 2026	Keybanc	Paul Knight	PT Cut	Overweight	$8→$5
May 22, 2026	Lake Street	Thomas Flaten	PT Cut	Buy	$8→$7
Jul 28, 2025	Lake Street	Thomas Flaten	Initiate	Buy	$8
Feb 12, 2025	Keybanc	Paul Knight	Initiate	Overweight	$8

Analyst Ratings News

PRO
Roth Capital Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $3

Roth Capital analyst Max Masucci initiates coverage on Rapid Micro Biosystems (NASDAQ:RPID) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk

PRO
Keybanc Maintains Overweight on Rapid Micro Biosystems, Lowers Price Target to $5

Keybanc analyst Paul Knight maintains Rapid Micro Biosystems (NASDAQ:RPID) with a Overweight and lowers the price target from $8 to $5.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on Rapid Micro Biosystems, Lowers Price Target to $7

Lake Street analyst Thomas Flaten maintains Rapid Micro Biosystems (NASDAQ:RPID) with a Buy and lowers the price target from $8 to $7.

Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $8

Lake Street analyst Thomas Flaten initiates coverage on Rapid Micro Biosystems (NASDAQ:RPID) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections

U.S. stock futures rose on Friday following Thursday's sell-off. Futures advanced except the small-cap gauge Russell 2000.

Rishabh Mishra

PRO
Keybanc Initiates Coverage On Rapid Micro Biosystems with Overweight Rating, Announces Price Target of $8

Keybanc analyst Paul Knight initiates coverage on Rapid Micro Biosystems (NASDAQ:RPID) with a Overweight rating and announces Price Target of $8.

Benzinga Newsdesk

Rapid Micro Biosystems Inc

Rapid Micro Biosystems Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Roth Capital Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $3

PRO
Keybanc Maintains Overweight on Rapid Micro Biosystems, Lowers Price Target to $5

PRO
Lake Street Maintains Buy on Rapid Micro Biosystems, Lowers Price Target to $7

PRO
Lake Street Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $8

US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections

PRO
Keybanc Initiates Coverage On Rapid Micro Biosystems with Overweight Rating, Announces Price Target of $8

People Also Watch

People Also Watch

Rapid Micro Biosystems Inc

Rapid Micro Biosystems Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORoth Capital Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $3

PROKeybanc Maintains Overweight on Rapid Micro Biosystems, Lowers Price Target to $5

PROLake Street Maintains Buy on Rapid Micro Biosystems, Lowers Price Target to $7

PROLake Street Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $8

US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections

PROKeybanc Initiates Coverage On Rapid Micro Biosystems with Overweight Rating, Announces Price Target of $8

People Also Watch

People Also Watch

PRO
Roth Capital Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $3

PRO
Keybanc Maintains Overweight on Rapid Micro Biosystems, Lowers Price Target to $5

PRO
Lake Street Maintains Buy on Rapid Micro Biosystems, Lowers Price Target to $7

PRO
Lake Street Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $8

PRO
Keybanc Initiates Coverage On Rapid Micro Biosystems with Overweight Rating, Announces Price Target of $8